Health Trials

Microsatellite Stable (MSS) Colorectal Cancer (CRC)

2

Review clinical trials related to Microsatellite Stable (MSS) Colorectal Cancer (CRC). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC

Thsi study is a randomised, parallel-controlled phase II/III trial evaluating FOLFIRI plus bevacizumab with or without QL1706 as second-line therapy for metastatic colorectal cancer. The primary endpoint is PFS. Secondary endpoint includes overall survival, objective response rate, safety profiles, immune-related adverse events, and patient quality of life. Exploratory analyses focus on dynamic shifts in tumour immune microenvironment and biomarkers, aiming to identify predictive signatures for therapeutic efficacy and immune toxicities.

Participants needed: 270
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Jul 27, 2026Locations: 1
Eligibility criteria

1. Willing and able to provide written informed consent. 2. Age ≥ 18 years old....

1.Patients complicated with digestive tract diseases including duodenal ulcer, u...

Read more
Status: Not yet recruiting

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

SBRT Combined with CAPEOX, Bevacizumab, and PD-1 Inhibitor in RAS-Mutant, Microsatellite Stable (MSS), Unresectable Metastatic Colorectal Cancer (mCRC): a Single-center, Single-arm, Open-label Clinical Trail

Participants needed: 28
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital with Nanjing Medical UniversityUpdated: Feb 19, 2025
Eligibility criteria

Aged 18-75 years, regardless of gender. [+13]

Patients who have received antibodies against programmed death receptor-1 (PD-1)... [+9]

Read more